Allergan pays $750m to resolve antitrust litigation
29-10-2019
Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug
20-08-2019
Aleksandra Gigowska / Shutterstock.com
New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Rising Pharmaceuticals, antitrust, competition, generics, criminal antitrust, US Department of Justice, hypertension drug
